The Philadelphia cell therapy company raised $15 million to advance the development of its lead new drug candidate targeting T-cell lymphoma, a rare form of cancer.

The Series A funding round was led by Valley Forge Investment Corp. and included investments from Agent Capital, Tellus BioVentures, the University of Pennsylvania, BioAdvance, NYBC Ventures, and The Leukemia & Lymphoma Society Therapy Acceleration Program.

“This financing brings us one step closer to validating the promise of our Senza5 platform technology and to delivering life-changing therapeutic [medicines] to patients dealing with some of the most difficult to treat diseases,” said Nicholas Siciliano, CEO of Vittoria.

Senza5, Vittoria’s proprietary CAR T-cell therapy engineering and manufacturing platform, combines genetic engineering and the company’s proprietary five-day cell therapy manufacturing process. The platform is based on technology exclusively licensed by Vittoria from the University of Pennsylvania.

Vittoria, founded in 2021 and based in University City, emerged from stealth mode during the summer of 2022 to announce a $10 million seed funding round.

Read More